Hims & Hers Health Registered (A) WKN: A2QMYY ISIN: US4330001060 Forum: Aktien Thema: Hauptdiskussion

Dein Wort entscheidet heute über meinen finanziellen Erfolg !😂🚀🚀🚀🚀🚀🚀🚀🚀🚀

Eigentlich sollte ja dann sehr bald das Menopauseding kommen, da der lab Test ja angelaufen ist, was sicherlich das aufwändigste ist 😁

Nein geh raus, weil dann steigen wir auf jeden Fall 🤣 Ne aber im Ernst: noch ist ja nichts verloren. Ich würde glaube ich heute noch abwarten

Hmmm 🤨 bleibe ich doch noch mit meinem Schein drin ?! 🤔🤔🤔

Keine Ahnung. Wird schon bald so weit sein denke ich. Quelle hatte schon Testosteron richtig vorhergesagt.

Hmmm 🤨 bleibe ich doch noch mit meinem Schein drin ?! 🤔🤔🤔

Und ab wann?

HRT/MENOPAUSE LAUNCH PREVIEW… 🚨 HERS CMO makes post promoting HRT Estrogen patches. Research indicates HERS to launch: -Estradiol tablets -Estradiol transdermal patches -Estradiol cream -Progesterone capsules 💲 Subscriptions likely ~ $159-199/month (labs waived)

🚨 BREAKING: $HIMS RECEIVED A CEASE-AND-DESIST LETTER FROM THE FDA LAST WEEK OVER ITS COMPOUNDED GLP-1 ADVERTISEMENTS VERY IMPORTANT: The letter does NOT tell Hims to stop selling compounded GLP-1s. The warning is specifically about marketing language. The letter: "Your claims imply that your product is the same as an FDA-approved product when it is not." The letter also said that Hims' website made claims that were "false or misleading," and that the product "misbranded." $HIMS response: "As we've previously stated, our Super Bowl ad did not advertise any one treatment or solution... Rather, it aimed to raise awareness to a critical issue — the obesity public health crisis — by showcasing the impact of obesity and the realities of the lack of access to life-saving holistic weight loss care." Additionally, Hims said it is "engaging with the FDA to address any concerns and ensure continued access to safe and affordable health care", and that its GLP-1s "are produced in industry-leading facilities, with ingredients from FDA-regulated manufacturers, and undergo rigorous quality testing." The FDA is expecting Hims to immediately address the "violations," take down any misleading language, and must write to the FDA to explain how it will avoid similar missteps in the future. 🤯